News Column

Researchers at Seoul National University Hospital Report Findings in Stent Thrombosis (Biodegradable-polymer drug-eluting stents vs. bare metal...

July 14, 2014



Researchers at Seoul National University Hospital Report Findings in Stent Thrombosis (Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network ...)

By a News Reporter-Staff News Editor at Cardiovascular Week -- Current study results on Stent Thrombosis have been published. According to news reporting out of Seoul, South Korea, by NewsRx editors, research stated, "The aim of this study was to compare the safety and efficacy of biodegradable-polymer (BP) drug-eluting stents (DES), bare metal stents (BMS), and durable-polymer DES in patients undergoing coronary revascularization, we performed a systematic review and network meta-analysis using a Bayesian framework. Study stents included BMS, paclitaxel-eluting (PES), sirolimus-eluting (SES), endeavor zotarolimus-eluting (ZES-E), cobalt-chromium everolimus-eluting (CoCr-EES), platinium-chromium everolimus-eluting (PtCr-EES), resolute zotarolimus-eluting (ZES-R), and BP biolimus-eluting stents (BP-BES)."

Our news journalists obtained a quote from the research from Seoul National University Hospital, "After a systematic electronic search, 113 trials with 90 584 patients were selected. The principal endpoint was definite or probable stent thrombosis (ST) defined according to the Academic Research Consortium within 1 year. Biodegradable polymer-biolimus-eluting stents [OR, 0.56; 95% credible interval (CrI), 0.33-0.90], SES (OR, 0.53; 95% CrI, 0.38-0.73), CoCr-EES (OR, 0.34; 95% CrI, 0.23-0.52), and PtCr-EES (OR, 0.31; 95% CrI, 0.10-0.90) were all superior to BMS in terms of definite or probable ST within 1 year. Cobalt-chromium everolimus-eluting stents demonstrated the lowest risk of ST of all stents at all times after stent implantation. Biodegradable polymer-biolimus-eluting stents was associated with a higher risk of definite or probable ST than CoCr-EES (OR, 1.72; 95% CrI, 1.04-2.98). All DES reduced the need for repeat revascularization, and all but PES reduced the risk of myocardial infarction compared with BMS. All DESs but PES and ZES-E were superior to BMS in terms of ST within 1 year. Cobalt-chromium everolimus-eluting stents was safer than any DES even including BP-BES."

According to the news editors, the research concluded: "Our results suggest that not only the biodegradability of polymer, but the optimal combination of stent alloy, design, strut thickness, polymer, and drug all combined determine the safety of DES."

For more information on this research see: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. European Heart Journal, 2014;35(17):1147-58. (Oxford University Press - www.oup.com/; European Heart Journal - eurheartj.oxfordjournals.org)

Our news journalists report that additional information may be obtained by contacting S.H. Kang, Dept. of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, 28 Yeongeon-Dong, Chongno-gu, Seoul 110-744, South Korea. Additional authors for this research include K.W. Park, D.Y. Kang, W.H. Lim, K.T. Park, J.K. Han, H.J. Kang, B.K. Koo, B.H. Oh, Y.B. Park, D.E. Kandzari, D.J. Cohen, S.S. Hwang and H.S Kim (see also Stent Thrombosis).

Keywords for this news article include: Asia, Seoul, South Korea, Stent Thrombosis.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cardiovascular Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters